GBC Precision Medicine | CellBio™ CTC Testing Technology and Services

2023-11-06

Source: General Biologicals Corporation (GBC) ( Healthcare+ Expo- booth no.: L130)

GBC Precision Medicine | CellBio™ CTC Testing Technology and Services
Revolutionizing Cancer Screening and Diagnosis

The 2023 Healthcare⁺ EXPO is scheduled to take place from November 30th to December 3rd, with a particular focus on AI healthcare and opportunities in the field of large-scale health applications. GBC Precision Medicine, a prominent leader in the industry, will have their booth located in the Precision Medicine Zone on the 4th floor, booth number: L130. They will be showcasing their latest equipment, the CellBio™ Circulating Tumor Cell (CTC) cancer detection product, along with an array of medical monitoring services and technologies. These offerings represent highly competitive professional in vitro diagnostic (IVD) devices and reagents.

This exhibition features three major themes: Smart Healthcare, Precision Medicine, and Lifelong Health. With a total of 2,500 exhibition booths, the event has seen remarkable growth, with participation from a diverse range of sectors, including hospitals, technology companies, and the biotechnology industry, all showing an increase of over 120%. Notably, it's not just the major medical centers but also more than 70 regional and specialized hospitals that are taking part. This exhibition showcases Taiwan's cutting-edge medical technology, clinical applications, and innovative validations, providing opportunities for both domestic and international businesses to collaborate and engage with potential procurement partners.

GBC’s purpose has remained the same — to create better and more affordable in-vitro diagnostics that are accessible to everyone. Our in-vitro diagnostic tests portfolio including respiratory infections, blood virology, women’s and sexual health, oncology and human genetics and emerging infectious diseases, and equipment are now the trusted solution for hospital professionals, lab technicians, blood banks, and consumers worldwide.

GB CellBio™, utilizes an exclusive patented membrane separation method known as iFiltration™. It allows for the rapid and efficient capture of circulating tumor cells (CTCs) in human blood using a physical approach that preserves cell morphology and retains target antigens and other specific markers. For individuals undergoing the testing service, all that is required is to make an online appointment and provide a non-fasting blood sample of 7.5 c.c, a process that takes only 10-15 minutes. Reports are then sent out within 7 business days. This facilitates the assessment of treatment effectiveness, the precise formulation of personalized treatment plans, and the continuous monitoring of changes in CTC count, ensuring the effective understanding of treatment timing and outcomes.

Event: GBC Precision Medicine | CellBio™ CTC Testing Technology and Services

Date: December 1 (Friday) 16:30-17:00

Venue: Conference Room 404, South Hall 1, Exhibition Area

We look forward to your participation in this exciting medical exhibition, contributing to the advancement and innovation in medical technology. If you are interested in attending or need further information about the exhibition, please click the "Schedule a Meeting" button and select a time slot. We will arrange for a representative to meet with you during the chosen time.

Made to Work – Patented Size iFiltration™ Technology , ● Rapid Results. ●95% recovery rate. ● Single cell sensitivity, High capacity up to 10 samples at once (CellBio™ FX10), Simple to Operate with Quality Assurance:●Operating time 15 minutes. ●No sample prep, purification, or enrichment. ●QC check point implemented to ensure quality of the experiment.
Made to Work – Patented Size iFiltration™ Technology , ● Rapid Results. ●95% recovery rate. ● Single cell sensitivity, High capacity up to 10 samples at once (CellBio™ FX10), Simple to Operate with Quality Assurance:●Operating time 15 minutes. ●No sample prep, purification, or enrichment. ●QC check point implemented to ensure quality of the experiment.